Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.

Also called NCT02916706

  • Study
  • In this atlas

Overview

Design
Interventional study; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 254 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02916706
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02916706. Quadruple masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2018-08-14 (actual). Results posted on 2022-01-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Teneligliptin 20mg
Intervention (Drug)
Placebo
Lead sponsor
Tanabe Pharma Corporation (class: industry)

Record details

Record id
cardio:ct-nct02916706
Content hash
5e251d65cccf6b52f7916c3681669ac1f5dfbfa7de0d3ea18c959ab478db4804